Kin Eigaku

Affiliation and department：
Papers (113)：

Osamu Kanai, Young Hak Kim, Yoshiki Demura, Makiko Kanai, Tsuyoshi Ito, Kohei Fujita, Hironori Yoshida, Masaya Akai, Tadashi Mio, Toyohiro Hirai. Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. Thoracic cancer. 2018. 9. 7. 847-855
Hiroaki Akamatsu, Nobuyuki Katakami, Isamu Okamoto, Terufumi Kato, Young Hak Kim, Fumio Imamura, Masaharu Shinkai, Rachel A Hodge, Hirohiko Uchida, Toyoaki Hida. Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial. Cancer science. 2018. 109. 6. 1930-1938
Hosomi Y, Tanai C, Yoh K, Goto Y, Sakai H, Kato T, Kaburagi T, Nishio M, Kim YH, Inoue A, et al. Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression. Expert opinion on pharmacotherapy. 2018. 19. 10. 1-8
Daichi Fujimoto, Hiroshige Yoshioka, Yuki Kataoka, Takeshi Morimoto, Young Hak Kim, Keisuke Tomii, Tadashi Ishida, Masataka Hirabayashi, Satoshi Hara, Manabu Ishitoko, et al. Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study. Lung Cancer. 2018. 119. 14-20
Hamaji M, Motoyama H, Menju T, Chen-Yoshikawa TF, Sonobe M, Kim YH, Date H. Thoracoscopic rebiopsy to detect the T790M mutation after postoperative recurrence. Interactive cardiovascular and thoracic surgery. 2018. 27. 4. 606-608

ｍore...

MISC (166)：

ｍore...

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page